Working together to deliver cell and gene therapies for people impacted by serious diseases Learn More Our inspiration Learn More Pipeline Explore R&D pz-cel (prademagene zamikeracel) BLA submitted for investigational autologous, COL7A1 gene-corrected epidermal sheets for RDEB. Learn More ABO-50X Exploring the potential of ABO-50X for the treatment of genetic eye disorders. Learn More Latest News May 3, 2024 Abeona Therapeutics Announces Pricing of $75 Million Underwritten Offering of Common Stock and Pre-Funded Warrants View Press Release Apr 22, 2024 Abeona Therapeutics Provides Regulatory Update on Pz-cel View Press Release Apr 1, 2024 Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) View Press Release View All Manufacturing at The Elisa Linton Center for Rare Disease Therapies Learn More